Menu

Theranos Withdraws Zika Blood Test

The embattled company failed to include proper safeguards, according to federal regulators.

Sep 1, 2016
Jef Akst

Elizabeth Holmes, CEO and founder of TheranosWIKIMEDIA, GLENN FAWCETTTheranos’s best hope for a comeback—a blood-based test called miniLab—is already in hot water. According to a news release, Theranos researchers demonstrated the success of their Zika blood test on the device, but officials at the US Food and Drug Administration (FDA) now say that the company did not implement proper patient-safety protocols, The Wall Street Journal (WSJ) reported. Theranos, which made headlines earlier this year for troubles with substandard laboratory conditions and allegations of criminal activity, has now withdrawn its request for emergency clearance of the Zika test.

“We hope that our decision to withdraw the Zika submission voluntarily is further evidence of our commitment to engage positively with the agency,” Dave Wurtz, Theranos’s vice president of regulatory, quality and clinical affairs, told WSJ.

When CEO Elizabeth Holmes, who was banned from operating a lab for two years after the company was caught selling inaccurate blood tests to consumers, announced the miniLab’s launch at the American Association for Clinical Chemistry (AACC) conference earlier this month (August 1), she claimed that the blood-based test would one day be able to run 160 different assays, from lipid panels to Zika tests. That same day, the company put out a press release stating that it had already tested the device on blood samples collected by finger pricks from patients, including those in the Dominican Republic, and had submitted “validation data for this Zika assay to the FDA for an Emergency Use Authorization.” But according to sources cited by the WSJ, some data in that submission had not followed review-board-approved protocols.

“As with the last phases, Theranos’ implementation of the miniLab may have played too fast and loose with federal regulations,” The Verge reported.

According to WSJ, Theranos investors received an email from the company last Saturday stating that it plans to collect additional data and resubmit an FDA application for emergency clearance of the Zika test, and that it would eventually do the same for an Ebola test.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.